These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19153552)

  • 21. Use of activated protein C (drotrecogin alfa) in a patient with sepsis and respiratory failure on ultra high frequency jet ventilation.
    Datta D; McNamee M
    Conn Med; 2003 Jan; 67(1):11-2. PubMed ID: 12630184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. We've made progress in the treatment of sepsis, so do we still need sepsis trials?
    Vincent JL
    Minerva Anestesiol; 2013 Jan; 79(1):1-2. PubMed ID: 23299044
    [No Abstract]   [Full Text] [Related]  

  • 23. Recombinant human activated protein C for severe sepsis.
    Ott A; Verbrugh HA
    N Engl J Med; 2001 Jul; 345(3):220; author reply 220-1. PubMed ID: 11463023
    [No Abstract]   [Full Text] [Related]  

  • 24. My brother has severe sepsis--should he receive Xigris?
    Suter PM
    Minerva Anestesiol; 2007 Dec; 73(12):647-50. PubMed ID: 18046295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paving a new road for generating evidence-based care in sepsis*.
    Annane D
    Crit Care Med; 2014 Jul; 42(7):1743-4. PubMed ID: 24933058
    [No Abstract]   [Full Text] [Related]  

  • 26. [Can we still afford progress in intensive care medicine? Re: the article from DMW 1-2/2004].
    Kalenka A
    Dtsch Med Wochenschr; 2004 Jul; 129(31-32):1698-9; author reply 1699-70. PubMed ID: 15273924
    [No Abstract]   [Full Text] [Related]  

  • 27. Inflammation and coagulation: implications for the septic patient.
    Dellinger RP
    Clin Infect Dis; 2003 May; 36(10):1259-65. PubMed ID: 12746771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Coagulation tests during treatment with Drotrecogin alpha (activated): do results reflect the clinical situation?].
    Roca de Togores López A; Armero Ibáñez R; Seller Losada JM; Petusa Collado V; Onrubia Fuertes X; Sifre Julio C; Bellver Romero J; Barberá Alacreu M
    Rev Esp Anestesiol Reanim; 2005 Feb; 52(2):117-8. PubMed ID: 15765996
    [No Abstract]   [Full Text] [Related]  

  • 29. Recombinant human activated protein C: current insights into its mechanism of action.
    Levi M; van der Poll T
    Crit Care; 2007; 11 Suppl 5(Suppl 5):S3. PubMed ID: 18269690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical impact of novel anticoagulation strategies in sepsis.
    Opal SM
    Curr Opin Crit Care; 2001 Oct; 7(5):347-53. PubMed ID: 11805532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant human activated protein C for severe sepsis.
    Kapur S; Kupfer Y; Tessler S
    N Engl J Med; 2001 Jul; 345(3):219-20; author reply 220-1. PubMed ID: 11463021
    [No Abstract]   [Full Text] [Related]  

  • 32. Recombinant human activated protein C for severe sepsis.
    Greisman SE; Johnston CA; Gosnell MS
    N Engl J Med; 2001 Jul; 345(3):219; author reply 220-1. PubMed ID: 11463022
    [No Abstract]   [Full Text] [Related]  

  • 33. [Should patients with severe sepsis be treated with activated protein C?].
    Laake JH; Bergmann JB; Riddervold F; Bjørneklett A; Aukrust P; Frøland SS
    Tidsskr Nor Laegeforen; 2004 Mar; 124(6):782-4. PubMed ID: 15039808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
    McLeay AM
    Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drotrecogin alfa (activated) for severe sepsis.
    Maglio D
    Conn Med; 2002 Mar; 66(3):145-50. PubMed ID: 11957766
    [No Abstract]   [Full Text] [Related]  

  • 36. Tight glycemic control may favor fibrinolysis in patients with sepsis.
    Savioli M; Cugno M; Polli F; Taccone P; Bellani G; Spanu P; Pesenti A; Iapichino G; Gattinoni L
    Crit Care Med; 2009 Feb; 37(2):424-31. PubMed ID: 19114908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of action of drotrecogin alfa activated (rhAPC).
    Jilma B; Derhaschnig U
    Thromb Haemost; 2004 May; 91(5):1050. PubMed ID: 15116270
    [No Abstract]   [Full Text] [Related]  

  • 38. Still puzzled by additional data from the PROWESS study.
    Schultz MJ
    Crit Care Med; 2005 Sep; 33(9):2146; author reply 2146-7. PubMed ID: 16148509
    [No Abstract]   [Full Text] [Related]  

  • 39. [Recommendations for management of severe sepsis and septic shock. Surviving sepsis campaign].
    Martin C; Garnier F; Vallet B
    Ann Fr Anesth Reanim; 2005 Apr; 24(4):440-3. PubMed ID: 15826800
    [No Abstract]   [Full Text] [Related]  

  • 40. The use of drotrecogin alfa (activated) in severe sepsis during acute pancreatitis - two case studies.
    Machała W; Wachowicz N; Komorowska A; Gaszyński W
    Med Sci Monit; 2004 Jul; 10(7):CS31-6. PubMed ID: 15232511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.